Menu

Blog

May 25, 2022

First Patient Injected With Experimental Cancer-Killing Virus in New Clinical Trial

Posted by in categories: biotech/medical, genetics

An experimental cancer-killing virus has been administered to a human patient for the first time, with hopes the testing will ultimately reveal evidence of a new means of successfully fighting cancer tumors in people’s bodies.

The drug candidate, called CF33-hNIS (aka Vaxinia), is what’s called an oncolytic virus, a genetically modified virus designed to selectively infect and kill cancer cells while sparing healthy ones.

In the case of CF33-hNIS, the modified pox virus works by entering cells and duplicating itself. Eventually, the infected cell bursts, releasing thousands of new virus particles that act as antigens, stimulating the immune system to attack nearby cancer cells.

Leave a reply